PZ CORMAY S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.61 PLN | +0.99% |
|
+3.74% | +3.74% |
| Sales 2021 | 84.73M 21.06M 1.68B | Sales 2022 | 85.36M 21.22M 1.69B | Capitalization | 74.69M 18.57M 1.48B |
|---|---|---|---|---|---|
| Net income 2021 | 1M 249K 19.79M | Net income 2022 | -6M -1.49M -119M | EV / Sales 2021 | 1.09 x |
| Net cash position 2021 | 4.38M 1.09M 86.72M | Net cash position 2022 | 6.3M 1.57M 125M | EV / Sales 2022 | 0.8 x |
| P/E ratio 2021 |
60.5
x | P/E ratio 2022 |
-11.4
x | Employees | 222 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.99% | ||
| 1 week | +3.74% | ||
| Current month | +3.74% | ||
| 1 month | +3.74% | ||
| 3 months | -3.17% | ||
| 6 months | +5.90% | ||
| Current year | +3.74% |
1 week
0.58
0.61
1 month
0.570.62
Current year
0.570.68
1 year
0.550.84
3 years
0.551.63
5 years
0.553.36
10 years
0.557.59
| Managers | Title | Age | Since |
|---|---|---|---|
Flavio Finotello
CEO | Chief Executive Officer | - | 31/08/17 |
Marcin Sieczek
BRD | Director/Board Member | - | 02/01/23 |
| Corporate Officer/Principal | - | 25/08/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tomasz Markowski
CHM | Chairman | - | 29/06/16 |
Bartosz Marczuk
BRD | Director/Board Member | 52 | - |
Marcin Sieczek
BRD | Director/Board Member | - | 02/01/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.61 | +0.99% | 13 676 |
| 26/04/24 | 0.604 | +1.00% | 22,954 |
| 25/04/24 | 0.598 | -1.97% | 6,835 |
| 24/04/24 | 0.61 | +0.99% | 26,364 |
| 23/04/24 | 0.604 | +2.37% | 23,645 |
Delayed Quote Warsaw S.E., April 29, 2024 at 04:55 pm
More quotes
PZ Cormay SA is a Polish-based producer and wholesaler of diagnostic reagents and a distributor of the laboratory equipment. The Company is engaged in the design, manufacture and distribution of a range of products for clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation and specific protein recognition. It offers drugs, biochemical rapid tests and devices such as vacuettes and tubes. PZ Cormay SA provides also biochemical analyzers: ACCENT-300, ACCENT-200, PRESTIGE 24i and LIVIA; hematological analyzers: MYTHIC 18, among others, and urinalysis apparatus: IChem 100. On September 1, 2014, Orphee SA acquired 100% stake in TT Management Sp z o o to enable execution of the restructuring plan of Cormay group which aims at transferring production and distribution activity of Cormay group to Orphee SA.
| 1st Jan change | Capi. | |
|---|---|---|
| +3.74% | 12.56M | |
| +1.69% | 12.8B | |
| -7.57% | 7.61B | |
| +3.22% | 5.41B | |
| +0.93% | 4.51B | |
| +8.48% | 4.49B | |
| +9.21% | 2.73B | |
| -13.87% | 2.02B | |
| -11.63% | 1.73B | |
| +3.45% | 1.64B |
- Stock Market
- Equities
- CRM Stock
